SCHEMBL23138142

SCHEMBL23138142

CCOC(=O)[C@H](O)Cn1cnc(C)n1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
HIF1A Q16665 1/20 0.39
LMNA P02545 3/20 0.36
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
XPO1 O14980 2/20 0.33
CSNK1D P48730 1/20 0.33
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33
PTGS2 P35354 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
GAA P10253 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
JMJD6 Q6NYC1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29115650 1.00 CYP1A2 (0.39) CYP1A2CYP2C9HIF1ALMNAALDH1A1
SCHEMBL20703189 0.82 ALDH1A1 (0.39) LMNAALDH1A1SMN1; SMN2
SCHEMBL20703191 0.82 ALDH1A1 (0.39) LMNAALDH1A1SMN1; SMN2
SCHEMBL16770024 0.76 GSK3A (0.50) ALDH1A1SMN1; SMN2GSK3AGSK3BNPSR1
SCHEMBL20703040 0.75 THRB (0.45) CYP1A2CYP2C9HIF1ALMNASMN1; SMN2
SCHEMBL23139055 0.73 NLRP3 (0.46) CYP1A2SMN1; SMN2
SCHEMBL23118100 0.73 NLRP3 (0.46) CYP1A2SMN1; SMN2
SCHEMBL14908426 0.72 NPSR1 (0.41) CYP1A2CYP2C9LMNAALDH1A1SMN1; SMN2
SCHEMBL20713652 0.71 NLRP3 (0.51) CYP1A2CYP2C9HIF1ALMNAALDH1A1
SCHEMBL28420437 0.70 GAA (0.36) CYP1A2CYP2C9HIF1ALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223263-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2025-07-10 US disclosed
US-12247011-B2 Selective inhibitors of NLRP3 inflammasome NodThera Limited (GB) 2025-03-11 US disclosed
CN-111356680-B Selective inhibitors of NLRP3 inflammasome 诺瑟拉有限公司 2023-11-28 CN disclosed
EP-3661921-B1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NODTHERA LTD (GB) 2023-10-18 EP disclosed
US-20210087147-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2021-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247011-B2 Selective inhibitors of NLRP3 inflammasome NLRP3, NOD1, NLRP1 CYP1A2 2468/4885CYP2C9 2910/4885HIF1A 933/4885
US-20250223263-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, NOD1, NLRP1 CYP1A2 2468/4885CYP2C9 2910/4885HIF1A 933/4885
US-20210087147-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, NOD1, NLRP1 CYP1A2 2468/4885CYP2C9 2910/4885HIF1A 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.